These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 21528891)
1. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein. Pinto M; Orzaez Mdel M; Delgado-Soler L; Perez JJ; Rubio-Martinez J J Chem Inf Model; 2011 Jun; 51(6):1249-58. PubMed ID: 21528891 [TBL] [Abstract][Full Text] [Related]
2. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening. Mukherjee P; Desai P; Zhou YD; Avery M J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095 [TBL] [Abstract][Full Text] [Related]
3. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577 [TBL] [Abstract][Full Text] [Related]
4. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183 [TBL] [Abstract][Full Text] [Related]
5. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface. Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783 [TBL] [Abstract][Full Text] [Related]
6. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors. Yap JL; Cao X; Vanommeslaeghe K; Jung KY; Peddaboina C; Wilder PT; Nan A; MacKerell AD; Smythe WR; Fletcher S Org Biomol Chem; 2012 Apr; 10(15):2928-33. PubMed ID: 22395339 [TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors. Almerico AM; Tutone M; Lauria A Eur J Med Chem; 2010 Nov; 45(11):4774-82. PubMed ID: 20728251 [TBL] [Abstract][Full Text] [Related]
8. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929 [TBL] [Abstract][Full Text] [Related]
9. A new assay for the discovery of Bcl-XL inhibitors. Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143 [TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Finnegan NM; Curtin JF; Prevost G; Morgan B; Cotter TG Br J Cancer; 2001 Jul; 85(1):115-21. PubMed ID: 11437412 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051 [TBL] [Abstract][Full Text] [Related]
12. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL. Goreshnik I; Brock AM; Maly DJ Bioorg Med Chem Lett; 2011 Sep; 21(17):4951-5. PubMed ID: 21807512 [TBL] [Abstract][Full Text] [Related]
14. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein. Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970 [TBL] [Abstract][Full Text] [Related]
15. Interaction of a putative BH3 domain of clusterin with anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy. Lee DH; Ha JH; Kim Y; Bae KH; Park JY; Choi WS; Yoon HS; Park SG; Park BC; Yi GS; Chi SW Biochem Biophys Res Commun; 2011 May; 408(4):541-7. PubMed ID: 21527247 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors. Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848 [TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Kvansakul M; Yang H; Fairlie WD; Czabotar PE; Fischer SF; Perugini MA; Huang DC; Colman PM Cell Death Differ; 2008 Oct; 15(10):1564-71. PubMed ID: 18551131 [TBL] [Abstract][Full Text] [Related]
18. Oligomerization of BH4-truncated Bcl-x(L) in solution. Wang Y; Cao R; Liu D; Chervin A; Yuan J; An J; Huang Z Biochem Biophys Res Commun; 2007 Oct; 361(4):1006-11. PubMed ID: 17692289 [TBL] [Abstract][Full Text] [Related]
19. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL. Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284 [TBL] [Abstract][Full Text] [Related]